The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*

J.G. Youssef; Philip T. Lavin; David Schoenfeld; Richard A. Lee; Rainer Lenhardt; Jae‐Hyun Park; Javier Pérez Fernández; Melvin L. Morganroth; Jonathan C. Javitt; Dushyantha Jayaweera

doi:10.1097/ccm.0000000000005660

August 29, 2022Critical Care MedicineOpen Access

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*

View Full Paper

Ask AI

Bookmark

Share

Key Points

To determine whether synthetic vasoactive intestinal peptide (Aviptadil) improves 60-day survival and recovery from respiratory failure in critically ill COVID-19 patients compared with placebo.
Multicenter, placebo-controlled randomized trial conducted across 10 tertiary and community hospitals in the United States.
Enrolled 196 patients with COVID-19 respiratory failure randomized 2:1 to receive a 3-day course of intravenous Aviptadil or placebo.
The primary endpoint of alive and free from respiratory failure at day 60 did not reach statistical significance after adjusting for baseline ventilation status (OR, 1.6; 95% CI, 0.86-3.11).
Aviptadil significantly doubled the odds of overall survival at 60 days compared to placebo (OR, 2.0; 95% CI, 1.1-3.9; p = 0.035).
Patients receiving Aviptadil showed significant reduction in interleukin-6 levels by day 3 (p = 0.02) and an increased likelihood of survival among mechanically ventilated patients (p = 0.031).

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Randomized trial reveals improved 60-day survival with intravenous aviptadil in critical COVID-19 respiratory failure, suggesting therapeutic benefit despite missing the primary recovery endpoint.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Youssef et al. (2022) studied this question.

synapsesocial.com/papers/6a96ab45c00de92d9bfbc875 https://doi.org/10.1097/ccm.0000000000005660

View Full Paper

Ask AI

Bookmark

Share

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*

Key Points

No abstract yet

Implication

Discussion

Cite This Study

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading